Summer Sale Get Elite for just $199.50

00

Days

00

Hours

00

Mins

00

Sec

Claim Now

Black Diamond Therapeutics, Inc

Contributing Author

Recent Articles by Black Diamond Therapeutics, Inc

May-22	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference BDTX -35.77% GlobeNewswire
May-21	Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations BDTX GlobeNewswire
May-19	Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC BDTX +16.28% GlobeNewswire
May-07	Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update BDTX GlobeNewswire
Apr-21	Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting BDTX GlobeNewswire
Mar-16	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update BDTX GlobeNewswire
Mar-02	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences BDTX BDTX -5.35% GlobeNewswire
Dec-03	Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM BDTX -22.03% GlobeNewswire
Dec-02	Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update BDTX -8.49% GlobeNewswire
Nov-06	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences BDTX GlobeNewswire
Nov-06	Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update BDTX GlobeNewswire
Aug-07	Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update BDTX -15.24% GlobeNewswire
May-29	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference BDTX +13.07% GlobeNewswire
May-12	Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update BDTX +6.71% BDTX +10.29% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)